Cosmos Health Inc. COSM
0.32 USD +0.01 (+3.75%)
Nov 4, 2026, 10:15 AM EST
0.2964 Day range 0.3157
0.162 52-week range 0.82
- YTD
- -36.65%
- 1 year
- -53.26%
- Market cap
- 31.75M
- Revenue (ttm)
- 56.45M
- Profit margin
- -38.19%
- EPS (ttm)
- -0.65
- Shares out
- 23.26M
- Forward P/E
- -12.36
- YTD return
- -36.65%
- 1-year return
- -53.26%
- Volume
- 497.00K
- Avg volume
- 3.06M
- Open
- 0.2964
- Previous close
- 0.3041
- Day's range
- 0.2964 – 0.3157
- 52-week range
- 0.162 – 0.82
- Beta
- 3.14
- Price target
- 3.00 (+850.9%)
- Earnings date
- Aug 20, 2024
1Y -0.4181 (-57.75%)
Key statistics
- Enterprise value
- 22.63M
- PEG ratio
- 0.00
- Price / sales
- 0.25
- Price / book
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.80%
- Free cash flow
- -6.86M
- Total cash
- 365.02K
- Total debt
- 11.81M
- Return on equity
- -56.61%
- Short % of float
- 1.97%
- 50-day average
- 0.73594
- 200-day average
- 0.84244
Analyst view
Price target (mean) 3.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate -0.09.
Financials — quick view
COSM Revenue — quarterly 18.99M
COSM Net income — quarterly -6.09M
COSM EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.11 | -0.45 | -0.34 | -309.09% |
| Aug 20, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.14 | -0.09 | +0.05 | +35.71% |
| Aug 20, 2024 | Jun 1, 2024 | -0.14 | — | — | — |
| Aug 20, 2024 | Mar 1, 2024 | 0.00 | -0.04 | — | — |
| Aug 6, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About Cosmos Health Inc.
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Website
- cosmosholdingsinc.com
News
Cosmos Health Announces Expansion Of Its E-Commerce, Subscription Operations To Australia, New Zealand, Oceania Region 
Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway 
Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion 
Cosmos Health Expects Q4 Sales Of ~$15M, Gross Profit Of ~$10.5M With Gross Margin Of ~70% 
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days 
Cosmos Health Reaches 6,287 Active U.S. Subscriptions Generating ~$920K In Monthly Renewal Value; 60.5% Of Online Orders Include Subscriptions, Rising To More Than 75% In Recent Days As Adoption Accelerates 
Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription 
Cosmos Health Record One-Day U.S. Direct-To-Consumer Sales Of $92K+ On October 11 And $902K In 30 Days 
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days 
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Your note
Sign in to keep a note on COSM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASLIDIS ANASTASIOS | Director | Stock Award(Grant) | Apr 2, 2023 | 20,200 |
| BARDAKIS NIKOLAOS | Chief Operating Officer | Stock Award(Grant) | Apr 2, 2023 | 10,000 |
| HOIDAS JOHN JAMES | Director | Stock Award(Grant) | Apr 2, 2023 | 5,000 |
| IGNATIADES PAVLOS | Officer | Stock Award(Grant) | Apr 2, 2023 | 5,000 |
| SIOKAS GRIGORIOS | Chief Executive Officer | Purchase | Feb 15, 2024 | 1,394,600 |
| TERZIS GEORGIOS | Chief Financial Officer | Stock Award(Grant) | Oct 23, 2023 | 152,459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.13% | 1,658,850 | 1.03M | Sep 29, 2024 |
| Blackrock Inc. | 1.15% | 267,797 | 165.50K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.64% | 149,728 | 92.53K | Sep 29, 2024 |
| Vanguard Group Inc | 0.58% | 134,834 | 83.33K | Sep 29, 2024 |
| UBS Group AG | 0.50% | 115,667 | 71.48K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 24,743 | 15.29K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.58% | 134,834 | 83.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.39% | 89,961 | 55.59K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 22,653 | 14.00K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 21,794 | 13.47K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,515 | 2.79K | Oct 30, 2024 |